ERIC 2018: Dr. Stilgenbauer on Sequential and Combination Therapies in chronic lymphocytic leukemia (CLL)
This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
Dr. Ghia is a CLL researcher in Milano and president of ERIC (European Research Initiative on CLL) who discussed his vision for this first larger international meeting of ERIC where he hopes he can keep things on a scale that is more intimate and more constructive than what can happen when tens of thousands of hematologists meet at the ASH Annual Meeting and Exhibition and some of the other large hematology meetings. In fact, the plan is to limit attendance at future meetings by ERIC so that there can be meaningful smaller scale exchanges between researchers.
Here is my very brief interview with Dr. Ghia:
Meetings such as those by ERIC and iwCLL are critical as the only participants are CLL doctors and researchers. It means every session is focused on CLL and though they are smaller, they can be more impactful.
Stay strong. We are all in this together.
Brian Koffman MDCM (retired)
Related posts